Expression of HLA-DR and cytokine genes on interferon-γ-stimulated human salivary gland cell line

Pathobiology

Volumn 64, Issue 5, 1996, Pages 255-261

  Hamano, Hironori ^a   Haneji, Norio ^a   Yanagi, Kumiko ^a   Ishimaru, Naozumi ^a   Hayashi, Yoshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cytokine; HLA DR; Interferon ; Salivary gland

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENE INDUCTION; HISTOCOMPATIBILITY GENE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND;

CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS II; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; TUMOR CELLS, CULTURED;

EID: 0030497815     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000164056     Document Type: Article

References (40)

1. Bottazzo GF, Pujol-Borrel R, Hanafusa T: Role of aberrant HLA-DR expression and antigen-prescnlalion in induction of endocrine autoimmunity. Lancet 1983;ii: 1115-1118.
2. Unanuc E: Antigen-presenting function of the macrophage. Ann Rev Immunol 1984:2:395-428.
3. Bottazzo GF, Todd I, Mirakian R, et al: Organ-specific autoimmunity: A 1986 overview. Immunol Rev 1986:94:137-170.
4. Todd I, Aeha-Orbea H, Belt JI, et al: A molecular basis for MHC class II-associaied autoim-munity. Science 1988;240:1003-1009.
5. Hanafusa T, Pjol-Borrell R, Chiovato L, et al: Aberrant expression of HLA-DR antigen on thymocytes in Graves' disease: Relevance for autoimmunity. Lancet 1983:ii:1111-1115.
6. Londei M, Lamb JR, Bottazzo GF, Feldman M: Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 1984:312:639-641.
7. Todd I, Pujol-Borrell R, Abdul-Karim BAS et al: HLA-DR subregion expression by thyroid epithelium in autoimmune thyroid diseases and induced in vitro. Clin Exp Immunol 1987; 69:532-542.
8. Hamilton F, Black M, Farquharson MA. et al: Spatial correlation between thyroid epithelial cells expressing class II MHC molecules and interferon-y-containing lymphocytes in human thyroid autoimmune disease. Clin Exp Immunol 1991:83:64-68.
9. Miyasaka N, Sato K, Goto M, et al: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Arthritis Rheum 1988:31:480-486.
10. Bottazzo GF, Dean BM. McNally JM et al: In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985:313:353-360.
11. Foulis AK, Farquharson MA: Aberrant expression of HLA-DR antigens by insulin containing beta cells in recent onset type I (insulin dependent) diabetes mellitus. Diabetes 1986:35: 1215-1224.
12. Ballardini G, Mirakian R, Bianchi FB, et al: Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: Relevance to pathogenesis. Lancet 1984;ii: 1009-1013.
13. Jackson R, Mcnicol AM, Farquharson M, Foulis AK: Class II MHC expression in normal adrenal cortex and cortical cells in autoimmune Addison's disease. J Pathol 1988:155: 113-120.
14. Fox RI, Bumol T, Fantozzi R, et al: Expression of histocompatibility antigen HLA-DR by salivary gland epithelial cells in Sjogren's syndrome. Arthritis Rheum 1986:29:1105-1111.
15. Wectman AP, Volkman DJ, Gerrard TL, Fauci AS: The in vivo regulation of human thyrocytes HLA-DR antigen expression. J Clin Endocrinol Metab 1985;61:817-824.
16. Krakauer T, Oppenheim JJ: 1L-1 and tumor necrosis factor-a each up-regulate both the expression of IFN-γ receptors and enhance IFN-γ-induced HLA-DR expression of human monocytes and a human monocytic cell line (THP-1). J Immunol 1993;150:1205-1211.
17. Lee MS, Choby BY, Rim SY et al: Cycloheximide inhibits interferon-γ induced MHC class II antigen expression in cultured rat thyroid cells. Endocrinology 1991;128:1527-1531.
18. Todd I, Pujol-Borrell R, Hammond LJ, et al: Interferon-γ induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol 1985; 61:265-273.
19. Pujol-Borrell R, Todd I, Doshi M, et al: HLA class II induction in human islet cells by inter-feron-y plus tumor necrosis factor of lymphotoxin. Nature 1987;326:304-306.
20. Beutler B, Cerami A: Cachexin and tumor necrosis factor as two sides of the same biological coin. Nature 1986;320:584-588.
21. Jacob CO, McDevitt HO: Tumor necrosis factor-a in murine autoimmune lupus nephritis. Nature 1988:331:356-358.
22. Boswell JM, Yui MA, David DW, Kelley VE: Increased tumor necrosis factor and IL-1 β gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988:141:3050-3054.
23. Horii Y, Muraguchi A, Iwano M, et al: Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989;143:3949-3955.
24. Katz J, Nagler R, Bank S, et al: Cytokine modulate intcrleukin-6 production by human salivary gland cell line. Cell Immunol 1994; 159: 211-219.
25. Firestcin GS, Alvaro-Gracia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144:3347-3353.
26. Hirano T, Matsuda T, Turner M, et al: Excessive production of interleukin-6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-1801.
27. Manicourt D-H, Triki R, Fukuda K, et al: Levels of circulating tumor necrosis factor a and interlcukin-6 in patients with rheumatoid arthritis. Arthritis Rheum 1993;36:490-499.
28. Sato M, Hayashi Y. Yoshida H.et al: Search for specific markers of neoplastic epithelial duct and myoepithelial cell lines established from human salivary gland and characterization of their growth in vitro. Cancer 1984:54:2959-2967.
29. Chomczynski P, Sacchi M: Single-step method of RNA isolation by acid guanidium thiocya-nate-phenol-chloroform extraction. Anal Bio-chem 1987;162:156-159.
30. Steeg P, Moore R, Johnson H, Oppenheim J: Regulation of murine macrophage la antigen expression by a lymphokine with immune interferon activity. J Exp Med 1982; 156:1780-1793.
31. Pober J, Gimbrone M, Cotran R, et al: la expression by vascular endothelium is inducible by activated T-cells and by human gamma interferon. J Exp Med 1983;157:1339-1353.
32. Adorini L, Muller S, Cardinaux F, et al: In vivo competition between self peptides and foreign antigens in T cell activation. Nature 1988:334: 623-625.
33. Muller S, Adorini L, Juretic A, Nagy ZA: Selective in vivo inhibition of T cell activation by class II MHC-binding peptides administered in soluble form. J Immunol 1990; 145:4006-4011.
34. smolecules. J Immunol 1990:145:1687-1693.
35. Writh DC, Smilec DE, Michell DJ et al: Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell 1989;59:247-255.
36. Hurtenbach U, Lier E, Adorini L, Nagy ZA: Prevention of autoimmune diabetes in non-obesediabetic mice by treatment with a class II major histocompatibility complex-blocking peptide. J Exp Med 1993;177:1499-1504.
37. epr mice. J Êxp Med 1994:179:1137-1143.
38. Bloch KJ, Uchanan WWB, Wohl MJ, Bunim JJ: Sjögren's syndrome. A clinical, pathological and serological study of sixty-two cases. Medicine 1966;44:187-231.
39. Fox RI. Robinson CA, Curd JG, et al: Sjögren's syndrome, Proposed criteria for classification. Arthritis Rheum 1986;29:577-585.
40. Grubeck-Loebenstein B, Buchan G, Chantry D, et al: Analysis of intra thyroid cytokine production in thyroid autoimmune disease: Thyroid follicular cells produce interleukin-1α and interleukin-6. Clin Exp Immunol 1989:77: 324-330.